Docteur ELISABETH FONTANGES

Bibliographie

• Evaluation of circulating microRNA signature in patients with erosive hand osteoarthritis: The HOAmiR study

  2024

  ArticleOsteoarthritis and Cartilage

• Early-Onset Osteoporosis: Molecular Analysis in Large Cohort and Focus on the PLS3 Gene

  2024

  ArticleCalcified Tissue International

• Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy

  2024

  ArticleJournal of Clinical Endocrinology and Metabolism

• Long-term follow-up of severe autosomal recessive SP7-related bone disorder

  2024

  ArticleBONE

• Dysregulation of MicroRNAs in Adult Osteogenesis Imperfecta: The miROI Study

  2023

  ArticleJournal of Bone and Mineral Research

• Osteogenesis Imperfecta: characterization of fractures during pregnancy and post-partum

  2022

  ArticleOrphanet Journal of Rare Diseases

• COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

  2021

  ArticleThe Lancet Rheumatology

• Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

  2020

  ArticleAnnals of the Rheumatic Diseases

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Bone loss after orthotopic liver transplantation

  The American journal of medicine · 1994

  📚 133 citations🎯 RCR 5.62Top 6% NIH
• 2

  Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2006

  📚 71 citations🎯 RCR 2.22Top 24% NIH🩺 Clinique

  Lire l'abstract Crossref ↓

  Abstract A 3-year, randomized, double-blind, placebo-controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta. The mean increases in the lumbar spine BMD were 10.1 ± 9.8% (p < 0.001) and 0.7 ± 5.7% in the alendronate and placebo groups, respectively. Oral alendronate increases BMD in adult patients with osteogenesis imperfecta. Introduction: This study evaluated the effect of oral alendronate on the BMD of adult patients with osteogenesis imperfecta. Materials and Methods: We carried out a 3-year, randomized, double-blind, placebo-controlled trial of oral alendronate in 64 adult patients with osteogenesis imperfecta. The primary endpoint was the difference between the groups in the mean percent change in lumbar spine BMD at 3 years. Secondary outcomes included changes in BMD of total hip, vertebral and peripheral fracture incidence, pain, hearing loss, and bone turnover biochemical markers. Patients were treated daily with either placebo or 10 mg alendronate. All received 1 g of calcium and 800 IU of vitamin D daily. Results: The mean ± SD increases in the lumbar spine BMD were 10.1 ± 9.8% (p < 0.001) and 0.7 ± 5.7% in the alendronate and placebo groups, respectively. Hip BMD increased in the alendronate group by 3.3 ± 0.5% (p = 0.001) and decreased in the placebo group by 0.3 ± 0.6%. The sample size was not sufficient to determine an effect of alendronate on fracture rate. A significant increase of the pain score was noted in the alendronate group (p = 0.04) in the intent-to-treat analysis but not in the per protocol analysis. There was no change in hearing in either group. Bone resorption and formation biochemical markers were significantly decreased in the alendronate group (p < 0.001). There were no differences in severe adverse effects between the groups, but there was an increase in nonsevere upper gastrointestinal effects in the alendronate group (p = 0.003). Conclusions: Oral alendronate increases BMD and increase nonsevere gastrointestinal adverse effects but does not modify the hearing loss in adult patients with osteogenesis imperfecta. More studies are needed to evaluate an effect on the fracture rate.

• 3

  Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus

  Rheumatology (Oxford, England) · 2007

  📚 51 citations🎯 RCR 1.63🩺 Clinique

Publications scientifiques (20) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche